raloxifene has been researched along with Breast Neoplasms in 16 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Almost 70% of breast cancers are estrogen receptor α (ERα) positive." | 5.43 | Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. ( Carlson, K; Delgado-Rivera, L; Gutgesell, LM; Katzenellenbogen, JA; Martin, T; Moore, TW; Patel, HK; Pham, TND; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2016) |
| "The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials." | 3.91 | Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer. ( Chen, H; Dubrovyskyii, O; Dye, K; Gordon-Blake, J; Gutgesell, LM; He, D; Hollas, M; Huang, F; Lasek, AW; Lee, S; Li, Y; Lu, Y; Rosales, CI; Shen, Z; Thatcher, GRJ; Tonetti, DA; Wang, Y; Xiong, R; Zhao, H; Zhao, J, 2019) |
| "Almost 70% of breast cancers are estrogen receptor α (ERα) positive." | 1.43 | Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. ( Carlson, K; Delgado-Rivera, L; Gutgesell, LM; Katzenellenbogen, JA; Martin, T; Moore, TW; Patel, HK; Pham, TND; Thatcher, GRJ; Tonetti, DA; Xiong, R; Zhao, H; Zhao, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, CD | 2 |
| Blaszczak, LC | 1 |
| Goettel, ME | 1 |
| Suarez, T | 1 |
| Crowell, TA | 1 |
| Mabry, TE | 1 |
| Ruenitz, PC | 1 |
| Srivatsan, V | 1 |
| Grese, TA | 1 |
| Cho, S | 1 |
| Finley, DR | 1 |
| Godfrey, AG | 1 |
| Lugar, CW | 1 |
| Martin, MJ | 1 |
| Matsumoto, K | 1 |
| Pennington, LD | 1 |
| Winter, MA | 1 |
| Adrian, MD | 1 |
| Cole, HW | 1 |
| Magee, DE | 1 |
| Phillips, DL | 1 |
| Rowley, ER | 1 |
| Short, LL | 1 |
| Glasebrook, AL | 1 |
| Bryant, HU | 1 |
| Rosati, RL | 1 |
| Da Silva Jardine, P | 1 |
| Cameron, KO | 1 |
| Thompson, DD | 1 |
| Ke, HZ | 1 |
| Toler, SM | 1 |
| Brown, TA | 1 |
| Pan, LC | 1 |
| Ebbinghaus, CF | 1 |
| Reinhold, AR | 1 |
| Elliott, NC | 1 |
| Newhouse, BN | 1 |
| Tjoa, CM | 1 |
| Sweetnam, PM | 1 |
| Cole, MJ | 1 |
| Arriola, MW | 1 |
| Gauthier, JW | 1 |
| Crawford, DT | 1 |
| Nickerson, DF | 1 |
| Pirie, CM | 1 |
| Qi, H | 1 |
| Simmons, HA | 1 |
| Tkalcevic, GT | 1 |
| Smith, RA | 1 |
| Chen, J | 1 |
| Mader, MM | 1 |
| Muegge, I | 1 |
| Moehler, U | 1 |
| Katti, S | 1 |
| Marrero, D | 1 |
| Stirtan, WG | 1 |
| Weaver, DR | 1 |
| Xiao, H | 1 |
| Carley, W | 1 |
| Blizzard, TA | 1 |
| DiNinno, F | 1 |
| Chen, HY | 1 |
| Kim, S | 1 |
| Wu, JY | 1 |
| Chan, W | 1 |
| Birzin, ET | 1 |
| Yang, YT | 1 |
| Pai, LY | 1 |
| Hayes, EC | 1 |
| DaSilva, CA | 1 |
| Rohrer, SP | 1 |
| Schaeffer, JM | 1 |
| Hammond, ML | 1 |
| Scott, SA | 1 |
| Selvy, PE | 1 |
| Buck, JR | 1 |
| Cho, HP | 1 |
| Criswell, TL | 1 |
| Thomas, AL | 1 |
| Armstrong, MD | 1 |
| Arteaga, CL | 1 |
| Lindsley, CW | 1 |
| Brown, HA | 1 |
| Dettmann, S | 1 |
| Szymanowitz, K | 1 |
| Wellner, A | 1 |
| Schiedel, A | 1 |
| Müller, CE | 1 |
| Gust, R | 1 |
| Kumar, A | 1 |
| Tripathi, VD | 1 |
| Kumar, P | 1 |
| Gupta, LP | 1 |
| Trivedi, R | 1 |
| Bid, H | 1 |
| Nayak, VL | 1 |
| Siddiqui, JA | 1 |
| Chakravarti, B | 1 |
| Saxena, R | 1 |
| Dwivedi, A | 1 |
| Siddiquee, MI | 1 |
| Siddiqui, U | 1 |
| Konwar, R | 1 |
| Chattopadhyay, N | 1 |
| Arsenyan, P | 1 |
| Paegle, E | 1 |
| Domracheva, I | 1 |
| Gulbe, A | 1 |
| Kanepe-Lapsa, I | 1 |
| Shestakova, I | 1 |
| Xiong, R | 2 |
| Patel, HK | 1 |
| Gutgesell, LM | 2 |
| Zhao, J | 2 |
| Delgado-Rivera, L | 1 |
| Pham, TND | 1 |
| Zhao, H | 2 |
| Carlson, K | 1 |
| Martin, T | 1 |
| Katzenellenbogen, JA | 1 |
| Moore, TW | 1 |
| Tonetti, DA | 2 |
| Thatcher, GRJ | 2 |
| Shoda, T | 1 |
| Kato, M | 1 |
| Fujisato, T | 1 |
| Misawa, T | 1 |
| Demizu, Y | 1 |
| Inoue, H | 1 |
| Naito, M | 1 |
| Kurihara, M | 1 |
| Luo, G | 3 |
| Tang, Z | 1 |
| Lao, K | 1 |
| Li, X | 2 |
| You, Q | 2 |
| Xiang, H | 3 |
| Wu, C | 1 |
| Lin, X | 1 |
| Cai, X | 1 |
| Liu, L | 1 |
| Lu, Y | 1 |
| Li, Y | 1 |
| Rosales, CI | 1 |
| Hollas, M | 1 |
| Shen, Z | 1 |
| Gordon-Blake, J | 1 |
| Dye, K | 1 |
| Wang, Y | 1 |
| Lee, S | 1 |
| Chen, H | 1 |
| He, D | 1 |
| Dubrovyskyii, O | 1 |
| Huang, F | 1 |
| Lasek, AW | 1 |
| Bai, C | 1 |
| Ren, S | 1 |
| Wu, S | 1 |
| Zhu, M | 1 |
| Ejaz, I | 1 |
| Javed, MA | 1 |
| Jan, MS | 1 |
| Ikram, M | 1 |
| Sadiq, A | 1 |
| Ahmad, S | 1 |
| Rashid, U | 1 |
16 other studies available for raloxifene and Breast Neoplasms
| Article | Year |
|---|---|
Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.
Topics: Antineoplastic Agents; Binding, Competitive; Breast Neoplasms; Calmodulin; Cell Division; Estradiol; | 1992 |
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Topics: Adenocarcinoma; Animals; Binding Sites; Bone and Bones; Breast Neoplasms; Cell Division; Cholesterol | 1997 |
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Topics: Administration, Oral; Animals; Biological Availability; Bone Density; Breast Neoplasms; Cell Divisio | 1998 |
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
Topics: Benzofurans; Breast Neoplasms; Cell Line; Drug Design; Estrogen Receptor alpha; Estrogen Receptor be | 2002 |
Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Estrogen Antagonists; | 2005 |
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Topics: Breast Neoplasms; Drug Design; Enzyme Inhibitors; Humans; Isoenzymes; Neoplasm Invasiveness; Phospho | 2009 |
2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estro | 2010 |
Design and synthesis of 1,3-biarylsulfanyl derivatives as new anti-breast cancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2011 |
Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Magnetic Resonan | 2014 |
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Resi | 2016 |
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator.
Topics: Breast Neoplasms; Down-Regulation; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Protein | 2016 |
Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug | 2018 |
Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Dose-Respons | 2019 |
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Re | 2019 |
Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response | 2021 |
Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.
Topics: Breast Neoplasms; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fe | 2022 |